

Coulter). Subsequently, the cells were permeabilized, stained for intracellular IFN- γ and IL-4 using the FastImmune™ system (BD Pharmingen), resuspended in phosphate-buffered saline (PBS) containing 1% paraformaldehyde (PFA), and analysed on a flow cytometer ($\approx 10\,000$ gated events acquired per sample).

IFN- γ enzyme-linked immunospot (ELISPOT) assay

ELISPOT assays were performed as described previously with the following modifications [28–30]. HLA-A24 restricted peptide epitopes, squamous cell carcinoma antigen recognized by T cells 2 (SART2)₈₉₉ (SYTRLFLIL), SART3₁₀₉ (VYDYNCHVDL), multi-drug resistance protein 3 (MRP3)₇₆₅ (VYSDADIFL), MRP3₅₀₃ (LYAWEPSFL), MRP3₆₉₂ (AYVPQAWI), alpha-fetoprotein (AFP)₄₀₃ (KYIQESQAL), AFP₄₃₄ (AYTKKAPQL), AFP₃₅₇ (EYSRRHPQL), human telomerase reverse transcriptase (hTERT)₁₆₇ (AYQVCGPPL) (unpublished), hTERT₄₆₁ (VYGFVRACL) and hTERT₃₂₄ (VYAETKHFL) were used in this study. Negative controls consisted of an HIV envelope-derived peptide (HIVenv₅₈₄). Positive controls consisted of 10 ng/ml PMA (Sigma) or a CMV pp65-derived peptide (CMVpp65₃₂₈). The coloured spots were counted with a KS ELISPOT Reader (Zeiss, Tokyo, Japan). The number of specific spots was determined by subtracting the number of spots in the absence of antigen from the number of spots in its presence. Responses were considered positive if more than 10 specific spots were detected and if the number of spots in the presence of antigen was at least twofold greater than the number of spots in the absence of antigen.

Cytokine and chemokine profiling

Serum cytokine and chemokine levels were measured using the Bioplex assay (Bio-Rad, Hercules, CA, USA). Briefly, frozen serum samples were thawed at room temperature, diluted 1:4 in sample diluents, and 50 μ l aliquots of diluted sample were added in duplicate to the wells of a 96-well microtitre plate containing the coated beads for a validated panel of 27 human cytokines and chemokines (cytokine 27-plex antibody bead kit) according to the manufacturer's instructions. These included IL-1 β , IL-1Ra, IL-2, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, IL-12p70, IL-13, IL-15, IL-17, basic fibroblast growth factor (FGF), eotaxin, G-CSF, GM-CSF, IFN- γ , interferon gamma-induced protein (IP)-10, monocyte chemoattractant protein (MCP)-1, MIP-1 α , MIP-1 β , platelet-derived growth factor (PDGF)-BB, regulated upon activation normal T cell-expressed and secreted (RANTES), TNF- α and vascular endothelial growth factor (VEGF). Eight standards (ranging from 2 to 32 000 pg/ml) were used to generate calibration curves for each cytokine. Data acquisition and analysis were performed using Bio-Plex Manager software version 4.1.1.

Arginase activity

Serum samples were tested for arginase activity by conversion of L-arginine to L-ornithine [31] using a kit supplied by the manufacturer (BioAssay Systems, Hayward, CA, USA). Briefly, sera were treated with a membrane filter (Millipore, Billerica, MA, USA) to remove urea, combined with the sample buffer in wells of a 96-well plate, and incubated at 37°C for 2 h. Subsequently, the urea reagent was added to stop the arginase reaction. The colour produced was read at 520 nm using a microtitre plate reader.

Statistical analysis

Results are expressed as means \pm standard deviation (s.d.). Differences between groups were analysed for statistical significance by the Mann–Whitney *U*-test. Qualitative variables were compared by means of Fisher's exact test. The estimated probability of tumour recurrence-free survival was determined using the Kaplan–Meier method. The Mantel–Cox log-rank test was used to compare curves between groups. Any *P*-values less than 0.05 were considered statistically significant. All statistical tests were two-sided.


Results

Preparation of OK432-stimulated DCs

Adherent cells isolated from PBMCs of patients with cirrhosis and HCC (Table 1) were differentiated into DCs in the presence of IL-4 and GM-CSF. The cells were stimulated with 0.1 KE/ml OK432 for 3 days; $54.6 \pm 9.5\%$ (mean \pm s.d.; $n = 13$) of OK432-stimulated cells showed high levels of MHC class II (HLA-DR) and the absence of lineage markers including CD3, CD14, CD16, CD19, CD20 and CD56, in which $30.9 \pm 14.2\%$ were CD11c-positive (myeloid DC subset) and $14.8 \pm 11.2\%$ were CD123-positive (plasmacytoid DC subset), consistent with our previous observations [20]. As reported [32,33], greater proportions of the cells developed high levels of expression of the co-stimulatory molecules B7-1 (CD80) and B7-2 (CD86) and an activation marker (CD83) compared to DCs prepared without OK432 stimulation (Fig. 1a). Furthermore, the chemokine receptor CCR7 which leads to homing to lymph nodes [13,34] was also induced following OK432 stimulation.

To evaluate the endocytic and phagocytic ability of the OK432-stimulated cells, uptake of FITC-dextran was quantitated by flow cytometry (Fig. 1b). The cells showed lower levels of uptake due to maturation compared to DCs prepared without OK432 stimulation, while the OK432-stimulated cells derived from HCC patients preserved a moderate uptake capacity. As expected, the OK432-stimulated cells produced large amounts of cytokines IL-12 and IFN- γ (Fig. 1c). In addition, they displayed high cyto-

Fig. 1. Effects of OK432 stimulation on the properties of dendritic cells (DCs) generated from blood monocyte precursors in patients with cirrhosis and hepatocellular carcinoma (HCC) ($n = 13$). (a) Lineage cocktail 1 (lin⁻) human leucocyte antigen D-related (HLA-DR⁻) subsets with [OK432(+)] and without [OK432(-)] stimulation were analysed for surface expression of CD80, CD83, CD86 and CCR7. Dot plots of a representative case are shown in the left-hand panel. Mean percentages [\pm standard deviation (s.d.)] of positive cells are indicated in the right-hand panel. OK432 stimulation resulted in the expression of high levels of CD80, CD83, CD86 and CCR7 in the lin⁻human leucocyte antigen D-related (HLA-DR⁻) DC subset. (b) DC subsets with and without OK432 stimulation were incubated with fluorescein isothiocyanate (FITC) dextran for 30 min and the uptake was determined by flow cytometry. A representative analysis is shown in the upper panel. Mean fluorescence intensities (MFIs) (\pm s.d.) of the positive cells are indicated in the lower panel. OK432-stimulated cells showed lower levels of uptake due to maturation. (c) DC supernatants were harvested and the concentrations of interleukin (IL)-12 and interferon (IFN)- γ measured by enzyme-linked immunosorbent assay (ELISA). OK432-stimulated cells produced large amounts of the cytokines. The data indicate means \pm s.d. of the groups with and without the stimulation. All comparisons in (a–c) [OK432(+)] versus [OK432(-)] were statistically significant by the Mann-Whitney *U*-test ($P < 0.005$). (d) Tumoricidal activity of DCs assessed by incubation with ⁵¹Cr-labelled Hep3B, PLC/PRF/5 and T2 targets for 8 h at the indicated effector/target (E/T) cell ratios. OK432-stimulated cells displayed high cytotoxic activity against the target cells. The results are representative of the cases studied.



toxic activity against HCC cell lines (Hep3B and PLC/PRF/5) and a lymphoblastoid cell line (T2) although DCs without OK432 stimulation lysed none of the target cells to any great degree (Fig. 1d). Taken together, these results demonstrate that OK432 stimulation of IL-4 and GM-CSF-induced immature DCs derived from HCC patients promoted their maturation towards cells with activated phenotypes, high expression of a homing receptor, fairly well-preserved phagocytic capacity, greatly enhanced cytokine production and effective tumoricidal activity, consistent with previous observations [16,19].

Safety of OK432-stimulated DC administration

Prior to the administration of OK432-stimulated DCs to patients, the cells were confirmed to be safe in athymic nude mice to which 100-fold cell numbers/weight were injected subcutaneously (data not shown). Subsequently, OK432-stimulated DC administration was performed during TAE therapy in humans, in which DCs were mixed together with absorbable gelatin sponge (Gelfoam) and infused through an arterial catheter following iodized oil (Lipiodol) injection, as reported previously [20]. Adverse events were




Fig. 1. *Continued*

monitored clinically and biochemically after DC infusion (Table 2). A larger proportion (12 of 13) of the patients were complicated with high fever compared to those treated previously with immature DCs (five of 10) [20], due probably to the proinflammatory responses induced by OK432-stimulated DCs. However, there were no grades III or IV

National Cancer Institute Common Toxicity Criteria adverse events, including vomiting, abdominal pain, encephalopathy, myalgia, ascites, gastrointestinal disorders, bleeding, hepatic abscess or autoimmune diseases associated with DC infusion and TAE in this study. There was also no clinical or serological evidence of hepatic failure or autoimmune

Table 2. Adverse events.

Patient no.	Fever (days)	Vomiting	Abdominal pain	Encephalopathy	Others [†]
1	2	No	No	No	No
2	2	No	No	No	No
3	1	No	No	No	No
4	3	No	No	No	No
5	3	No	No	No	No
6	4	No	No	No	No
7	10	No	No	No	No
8	No	No	No	No	No
9	2	No	No	No	No
10	1	No	No	No	No
11	2	No	No	No	No
12	2	No	No	No	No
13	1	No	No	No	No

[†]Other adverse events include myalgia, ascites, gastrointestinal disorder, bleeding, hepatic abscess and autoimmune diseases.

response in any patients. Thus, concurrent treatment with OK432-stimulated DC infusions can be performed safely at the same time as TAE in patients with cirrhosis and HCC.

Recurrence-free survival following DC infusion

A further objective of this study was to determine clinical response following DC infusion. A group of historical controls treated with TAE without DC administration was reviewed for this study (Table 3). The clinical characteristics including tumour burden and hepatic reserve were comparable between patients treated with TAE and OK432-stimulated DC transfer ($n = 13$) and those historical controls with TAE but without DC administration ($n = 22$). We com-

pared the recurrence-free survival between these patient groups. Kaplan–Meier analysis indicated that patients treated with TAE and OK432-stimulated DC transfer had prolonged recurrence-free survival compared with the historical controls that had been treated with TAE alone (recurrence rates 360 days after the treatments; two of 13 and 12 of 22, respectively; $P = 0.046$, log-rank test) (Fig. 2). The results demonstrated that OK432-stimulated DC transfer during TAE therapy reduces tumour recurrence in HCC patients.

NK cell activity and intracellular cytokine responses in PBMCs

To assess systemic immunomodulatory effects of OK432-stimulated DC transfer, PBMCs were isolated 1 and 3 months after treatment and NK cell cytotoxicity against K562 erythroleukaemia target cells measured using the ⁵¹Cr-release assay (Fig. 3). The level of NK cell was unaltered following treatment. In addition, cytokine production capacity of lymphocyte subsets was quantitated by measuring intracellular IFN- γ and IL-4 using flow cytometry. There were also no significant changes in terms of cytokine production capacity in the CD4⁺, CD8⁺ and CD56⁺ subsets in the patients treated with OK432-stimulated DCs.

Immune responses to peptide epitopes derived from tumour antigens

To assess the effects on T cell responses to tumour antigens, PBMCs were obtained 4 weeks after DC infusion, pulsed with peptides derived from AFP, MRP3, SART2, SART3 and hTERT. IFN- γ production was then quantitated in an

Table 3. Clinical characteristics of patients treated with TAE + OK-DC and TAE alone.

	TAE + OK-DC	TAE	<i>P</i>
No. of patients	13	22	
Age (years)	68.2 \pm 9.1	70.0 \pm 7.6	n.s. [†]
Gender (M/F)	9/4	13/9	n.s. [‡]
White cell count ($\times 10^2/\mu\text{l}$)	34.4 \pm 11.6	41.4 \pm 18.9	n.s. [†]
Lymphocytes ($\times 10^2/\mu\text{l}$)	10.4 \pm 3.6	12.4 \pm 4.7	n.s. [†]
Platelets ($\times 10^4/\mu\text{l}$)	11.5 \pm 10.2	10.3 \pm 5.8	n.s. [†]
Hepaplastin test (%)	64.6 \pm 11.6	75.5 \pm 24.3	n.s. [†]
ALT (IU/l)	56.7 \pm 38.9	67.9 \pm 44.6	n.s. [†]
Total bilirubin (mg/dl)	1.3 \pm 0.7	1.1 \pm 0.6	n.s. [†]
Albumin (g/dl)	3.4 \pm 0.6	3.6 \pm 0.4	n.s. [†]
Non-cancerous liver parenchyma (no.)			
Chronic hepatitis	0	8	
Cirrhosis (Child–Pugh A/B/C)	13 (5/8/0)	14 (6/8/0)	n.s. [‡]
TNM stages (I/II/III/IV-A/IV-B)	0/4/9/0/0	3/8/11/0/0	n.s. [‡]
No. of tumours	2.5 \pm 1.3	1.9 \pm 1.3	n.s. [†]
Largest tumour (mm)	30.2 \pm 9.4	32.6 \pm 15.2	n.s. [†]
AFP	204.8 \pm 404.1	201.8 \pm 544.2	n.s. [†]

Results are expressed as means \pm standard deviation. [†]Mann–Whitney *U*-test. [‡]Fisher's exact test. TAE, transcatheter arterial embolization; OK-DC, OK432-stimulated dendritic cells; ALT, alanine transaminase; TNM, tumour–node–metastasis; AFP, alpha-fetoprotein; Child–Pugh, Child–Pugh classification; n.s., not significant.




Fig. 2. Recurrence-free survival of patients treated with transcatheter hepatic arterial embolization (TAE) with [TAE + OK-stimulated dendritic cells (DC); $n = 13$] and without (TAE: historical controls; $n = 22$) OK432-stimulated DC administration. Time zero is the date of TAE. All patients underwent ultrasound, computed tomography (CT) scan or magnetic resonance imaging (MRI) of the abdomen about 1 month after treatment and at a minimum of once every 3 months thereafter. Kaplan–Meier analysis indicated that TAE + OK-DC treatment prolonged recurrence-free survival compared with the TAE-alone group (recurrence rates 360 days after the treatments; two of 13 and 12 of 22, respectively; $P = 0.046$, log-rank test).

ELISPOT assay. Cells producing IFN- γ in response to stimulation with HLA-A24 [the most common HLA-A antigen (58.1%) in Japanese populations [35]]-restricted peptide epitopes derived from tumour antigens MRP3 and hTERT were induced in three of six HLA-A24-positive patients (numbers 2, 6 and 11) after treatment with TAE and OK432-stimulated DCs (Fig. 4). To understand the immunological and clinical significance of the T lymphocyte responses, PBMCs obtained from the historical control patients who had been treated with TAE without DC administration were also evaluated by ELISPOT. Similarly, positive reactions were observed in four (numbers t8, t19, t20 and t22) of six HLA-A24-positive patients. These data indicate that T lymphocyte responses to HLA-A24 restricted peptide epitopes of tumour antigens were induced following the TAE therapy, but no additional responses were observed as a result of OK432-stimulated DC transfer in the current study.

Serum levels of cytokines, chemokines and arginase activity

To screen for immunobiological responses induced following OK432-stimulated DC transfer, serum levels of cytokines and chemokines were measured simultaneously using the Bio-Plex multiplex suspension array system. The results were compared with the historical control patients treated with TAE without DC administration. Interestingly, serum con-





Fig. 3. Natural killer (NK) cell activity and intracellular cytokine production in peripheral blood mononuclear cells (PBMCs) of patients treated with OK432-stimulated dendritic cells (DCs) during transcatheter hepatic arterial embolization (TAE) therapy ($n = 13$). PBMCs were isolated before and 1 and 3 months after treatment and used for the analyses. Upper panel: NK cell cytotoxicity against K562 erythroleukaemia target cells was evaluated at the effector/target (E/T) cell ratios shown. NK cell activities were not changed following treatment. Middle and lower panels: PBMCs were stimulated with phorbol 12-myristate 13-acetate (PMA) and ionomycin, stained for CD4, CD8 and CD56 expression, permeabilized and stained for intracellular interferon (IFN)- γ and interleukin (IL)-4. Percentages of cytokine-positive cells were quantitated by flow cytometry. There were no significant changes in terms of cytokine production capacity in the CD4⁺, CD8⁺ and CD56⁺ subsets following the treatments. The data are given as means \pm standard deviation of the groups.

Fig. 4. Immune responses to human leucocyte antigen (HLA-DR⁻)-A24-restricted peptide epitopes derived from tumour antigens in HLA-A24-positive patients treated with OK432-stimulated DCs during transcatheter hepatic arterial embolization (TAE) therapy (numbers 2, 5, 6, 7, 10 and 11) and HLA-A24-positive historical controls treated with TAE without dendritic cell (DC) transfer (numbers t8, t14, t15, t19, t20 and t22). Peripheral blood mononuclear cells (PBMCs) were obtained before the infusion (open bars) and 1 month after the infusion (solid bars) pulsed with the peptides derived from squamous cell carcinoma antigen recognized by T cells 2 (SART2), SART3, multi-drug resistance protein 3 (MRP3), alpha-fetoprotein (AFP), human telomerase reverse transcriptase (hTERT) and interferon (IFN)- γ production was quantitated by enzyme-linked immunospot (ELISPOT). Negative controls consisted of a human immunodeficiency virus (HIV) envelope-derived peptide (HIVenv₅₈₄). Positive controls consisted of 10 ng/ml phorbol 12-myristate 13-acetate (PMA) or a cytomegalovirus (CMV) pp65-derived peptide (CMVpp65₃₂₈). The number of specific spots was determined by subtracting the number of spots in the absence of antigen from the number of spots in its presence. T lymphocyte responses to the peptide epitopes were induced following TAE therapy, but no additional responses were observed after DC transfer. Numbers denote specific spots beyond the upper limit of y-axis; n.d., not determined.



centrations of IL-9, IL-15 and TNF- α were greatly increased after OK432-stimulated DC infusion, in contrast to their reduction following TAE treatment alone (Fig. 5a). Furthermore, the chemokines eotaxin (CCL11) and MIP-1 β (CCL4) were induced markedly after DC transfer, although they were also decreased after TAE alone. These data indicate that transfer of OK432-stimulated DC during TAE therapy induced unique immune responses that may be mediated by the cytokines IL-9, IL-15 and TNF- α and the chemokines eotaxin and MIP-1 β .

In addition, serum arginase activity was reported to reflect numbers of myeloid-derived suppressor cells (MDSCs) that may inhibit T lymphocyte responses in cancer patients [36]. Therefore, serum arginase activity was measured after OK432-stimulated DC infusion, and it was found that it was

increased six- or sevenfold in patients treated with TAE. However, this increase was independent of the presence or absence of OK432-stimulated DC transfer (Fig. 5b). None the less, serum arginase activity was decreased again 4 weeks after treatment with both TAE and OK432-stimulated DC transfer but tended to be maintained at a high levels in patients treated with TAE without DC transfer. However, these differences did not reach statistical significance ($P > 0.05$). Because arginase activity is known to be relatively high in liver and HCC cells [37], the influence of tissue injury was assessed biochemically by measuring serum levels of ALT and LDH activities. We did not observe ALT or LDH elevation, indicating that the increase of arginase activity was not due to tissue damage following treatment. Collectively, these results demonstrate that infusion of OK432-stimulated




Fig. 5. Cytokine and chemokine profiling and arginase activity in sera of patients treated with OK432-stimulated dendritic cells (DCs) during transcatheter hepatic arterial embolization (TAE) therapy (TAE + OK-DC; $n = 13$) and the historical controls treated with TAE without DC transfer (TAE; $n = 22$). (a) Serum samples were examined for their content of a validated panel of cytokines and chemokines using the Bioplex assay. Percentage changes in serum levels 2 weeks after the treatments were calculated as follows: [(post-treatment level – pretreatment level)/pretreatment level] $\times 100$. The data are means \pm standard error of the mean (s.e.m.) of the groups. $*P < 0.05$ when compared by the Mann–Whitney U -test. (b) Serum samples were tested for arginase activity by conversion of L-arginine to L-ornithine, and for alanine aminotransferase (ALT) and lactic dehydrogenase (LDH) activities. While there was a trend for the arginase activity in the TAE + OK-DC group to decrease 4 weeks after treatment, the difference did not reach statistical significance ($P > 0.05$). Percentage changes in serum levels 2 weeks after the treatments were calculated as follows: [(post-treatment level – pretreatment level)/pretreatment level] $\times 100$. The data indicate means \pm s.e.m. of the groups.

DCs during TAE treatment may reduce the immunosuppressive activities of MDSCs, and assist in developing a favourable environment for the induction of anti-tumour immunity.

Discussion

Although many novel strategies, including immunotherapies, have been developed in an attempt to suppress tumour recurrence after curative treatments for HCC, recurrence rates and survival times have not been improved significantly [38]. In the current study, we first established that OK432-stimulated DC administration during TAE therapy did not cause critical adverse events in patients with cirrhosis and HCC. Most importantly, DC transfer resulted in prolonged recurrence-free survival after combination therapy with TAE and OK432-stimulated DC administration. In terms of the immunomodulatory effects of DC transfer, although NK cell activity, intracellular cytokine production and T lymphocyte-mediated immune responses were not altered in PBMCs from treated patients, serum levels of IL-9, IL-15 and TNF- α and the chemokines eotaxin and MIP-1 β were enhanced markedly after DC transfer. In addition, serum levels of arginase activity were decreased following DC transfer. Collectively, this study demonstrated the feasibility, safety and beneficial anti-tumour effects of OK432-stimulated DC infusion into tumour tissues for patients with cirrhosis and HCC, suggesting the ability of an active immunotherapeutic strategy to reduce tumour recurrence after locoregional treatment of HCC.

DCs were stimulated with OK432 prior to infusion into tumour tissues through an arterial catheter. OK432 was reported to activate DCs through its binding to TLR-2 and -4 [16,39] that can be used for cancer therapy [33]. The current results indicate that OK432 stimulation of immature DCs

from HCC patients promoted their maturation processes while preserving antigen uptake capacity and enhancing tumoricidal activity, consistent with previous observations [16,19] and supporting the current strategy in which OK432-stimulated DCs were infused directly into tumour tissues. Because the tumoricidal activity of unstimulated DCs was not observed in *in vitro* experiments, OK432 stimulation obviously altered the cytotoxic properties of DCs. One of the mechanisms of DC killing was reported to be CD40/CD40 ligand interaction [19]. Further studies are needed to determine the killing mechanisms of DCs derived from HCC patients in a direct [TNF, TNF-related apoptosis inducing ligand (TRAIL), Fas ligand, nitric oxide (NO) and perforin/granzyme] and indirect (MHC-restricted) manner [40–43]. Although the main mechanism by which OK432-stimulated DCs prolonged the recurrence-free survival was not elucidated, the tumoricidal activity of mature DCs was implicated in *in vivo* enhancement of antigen presentation, co-stimulation and inflammatory cytokine production.

Very recent reports document injection of OK432-stimulated DCs into patients with cancer of the gastrointestinal tract or pancreas [44,45], but their anti-tumour effects were not defined clearly. The current study shows for the first time that OK432-stimulated DCs induce beneficial anti-tumour responses when transferred into tumour tissues during TAE therapy. The anti-tumour responses may have been enhanced as a result of optimal activation of the DCs with OK432 or combining infusion of stimulated DCs with TAE therapy. Inappropriately activated DCs may be unable to generate sufficient numbers of properly activated effector T lymphocytes [46]. As shown in Fig. 1, all these alterations could contribute to the further enhancement of anti-tumour effects compared to those in our previous study with immature DCs [20]. Furthermore, the tumour cell death-promoting therapies, e.g. chemotherapy [47] and TAE [48], can be expected to enhance the effects of therapeutic cancer vaccines by redressing the immunosuppressive tumour environment.

NK cell activity and intracellular cytokine responses in CD4⁺ and CD8⁺ T lymphocytes and CD56⁺ NK cell subsets in PBMCs were not changed significantly in patients treated with OK432-stimulated DCs. Furthermore, we did not observe tumour antigen-specific T lymphocyte responses associated clearly with DC administration. The data suggest therefore that the immune responses induced by the therapy applied here were not detectable systemically. Because cytotoxic T lymphocyte responses were enhanced in patients receiving $> 3 \times 10^7$ cells [49,50], the numbers of transferred OK432-stimulated DCs were apparently not sufficient to induce responses detectable in the peripheral blood, but were enough to exert beneficial anti-tumour effects. In addition, many studies have concluded that cytotoxic T lymphocyte responses rarely predict clinical outcomes of DC-based immunotherapies [51,52] and that in many cases, also including our own studies

[28,30], tumour-specific effector T lymphocytes co-exist with the tumours. Consistent with these observations, the current results suggest that cytotoxic T lymphocyte responses in PBMCs are not reliable predictors of beneficial anti-tumour effects in patients treated with the current OK432-stimulated DC strategy.

Serum levels of the cytokines IL-9, IL-15 and TNF- α and the chemokines eotaxin and MIP-1 β were increased following OK432-stimulated DC transfer, but decreased after TAE therapy without DC administration. IL-9 and IL-15 belong to the cytokine receptor common gamma chain (γ_c ; CD132) family, a member of the type I cytokine receptor family expressed on most lymphocyte populations [53]. IL-9 exerts pleiotropic activities on T and B lymphocytes, mast cells, monocytes and haematopoietic progenitors [54,55]. IL-15 and TNF- α are known to prime T lymphocytes and NK cells when secreted by DCs [56] and to induce anti-tumour immune responses [57]. Eotaxin is known to selectively recruit eosinophils also contributing to anti-tumour effects [58,59], and MIP-1 β is a chemoattractant for NK cells, monocytes and a variety of other immune cells [60]. In addition, serum levels of arginase tended to decrease after DC transfer. Because serum arginase activity reflects the numbers of MDSCs that inhibit T lymphocyte responses in cancer patients [36], the patients treated with OK432-stimulated DCs might have developed lower levels of suppressor cells. Collectively, the results suggest that infusion of OK432-stimulated DCs may orchestrate the immune environment in the whole body that could enhance beneficial anti-tumour effects, although the precise molecular and cellular mechanisms associated with the actions of these cytokines and chemokines were not defined clearly in the current analysis.

Acknowledgements

The authors thank Kazumi Fushimi and Mariko Katsuda for technical assistance. We also thank the patients for participating in this trial. This work was supported in part by research grants from the Ministry of Education, Culture, Sports, Science, and Technology of Japan, the Ministry of Health, Labour and Welfare of Japan and the Japanese Society of Gastroenterology.

Disclosure

The authors have declared that no conflict of interest exists.

References

- 1 Omata M, Tateishi R, Yoshida H, Shiina S. Treatment of hepatocellular carcinoma by percutaneous tumor ablation methods: ethanol injection therapy and radiofrequency ablation. *Gastroenterology* 2004; **127**:S159–66.
- 2 Belghiti J. Resection and liver transplantation for HCC. *J Gastroenterol* 2009; **44** (Suppl. 19):132–5.

- 3 Nakamoto Y, Guidotti LG, Kuhlen CV, Fowler P, Chisari FV. Immune pathogenesis of hepatocellular carcinoma. *J Exp Med* 1998; **188**:341–50.
- 4 Ercolani G, Grazi GL, Ravaioli M *et al.* Liver resection for hepatocellular carcinoma on cirrhosis: univariate and multivariate analysis of risk factors for intrahepatic recurrence. *Ann Surg* 2003; **237**:536–43.
- 5 Shankaran V, Ikeda H, Bruce AT *et al.* IFN γ and lymphocytes prevent primary tumour development and shape tumour immunogenicity. *Nature* 2001; **410**:1107–11.
- 6 Vulink A, Radford KJ, Melief C, Hart DN. Dendritic cells in cancer immunotherapy. *Adv Cancer Res* 2008; **99**:363–407.
- 7 Banchereau J, Briere F, Caux C *et al.* Immunobiology of dendritic cells. *Annu Rev Immunol* 2000; **18**:767–811.
- 8 Lemos MP, Esquivel F, Scott P, Laufer TM. MHC class II expression restricted to CD8 α + and CD11b+ dendritic cells is sufficient for control of *Leishmania major*. *J Exp Med* 2004; **199**:725–30.
- 9 Ni K, O'Neill HC. The role of dendritic cells in T cell activation. *Immunol Cell Biol* 1997; **75**:223–30.
- 10 Andrews DM, Andoniou CE, Scalzo AA *et al.* Cross-talk between dendritic cells and natural killer cells in viral infection. *Mol Immunol* 2005; **42**:547–55.
- 11 Heiser A, Coleman D, Dannull J *et al.* Autologous dendritic cells transfected with prostate-specific antigen RNA stimulate CTL responses against metastatic prostate tumors. *J Clin Invest* 2002; **109**:409–17.
- 12 Banchereau J, Steinman RM. Dendritic cells and the control of immunity. *Nature* 1998; **392**:245–52.
- 13 Forster R, Schubel A, Breitfeld D *et al.* CCR7 coordinates the primary immune response by establishing functional microenvironments in secondary lymphoid organs. *Cell* 1999; **99**:23–33.
- 14 MartIn-Fontecha A, Sebastiani S, Hopken UE *et al.* Regulation of dendritic cell migration to the draining lymph node: impact on T lymphocyte traffic and priming. *J Exp Med* 2003; **198**:615–21.
- 15 Ratzinger G, Stoitzner P, Ebner S *et al.* Matrix metalloproteinases 9 and 2 are necessary for the migration of Langerhans cells and dermal dendritic cells from human and murine skin. *J Immunol* 2002; **168**:4361–71.
- 16 Nakahara S, Tsunoda T, Baba T, Asabe S, Tahara H. Dendritic cells stimulated with a bacterial product, OK-432, efficiently induce cytotoxic T lymphocytes specific to tumor rejection peptide. *Cancer Res* 2003; **63**:4112–18.
- 17 Okamoto M, Oshikawa T, Tano T *et al.* Mechanism of anticancer host response induced by OK-432, a streptococcal preparation, mediated by phagocytosis and Toll-like receptor 4 signaling. *J Immunother* 2006; **29**:78–86.
- 18 Pasare C, Medzhitov R. Toll pathway-dependent blockade of CD4+CD25+ T cell-mediated suppression by dendritic cells. *Science* 2003; **299**:1033–6.
- 19 Hill KS, Errington F, Steele LP *et al.* OK432-activated human dendritic cells kill tumor cells via CD40/CD40 ligand interactions. *J Immunol* 2008; **181**:3108–15.
- 20 Nakamoto Y, Mizukoshi E, Tsuji H *et al.* Combined therapy of transcatheter hepatic arterial embolization with intratumoral dendritic cell infusion for hepatocellular carcinoma: clinical safety. *Clin Exp Immunol* 2007; **147**:296–305.
- 21 Steinman RM, Banchereau J. Taking dendritic cells into medicine. *Nature* 2007; **449**:419–26.
- 22 Tacke PJ, de Vries IJ, Torensma R, Figdor CG. Dendritic-cell immunotherapy: from *ex vivo* loading to *in vivo* targeting. *Nat Rev Immunol* 2007; **7**:790–802.
- 23 Makuuchi M. General rules for the clinical and pathological study of primary liver cancer, 2nd edn. Tokyo: Kanehara & Co., Ltd, 2003.
- 24 Veltri A, Moretto P, Doriguzzi A, Pagano E, Carrara G, Gandini G. Radiofrequency thermal ablation (RFA) after transarterial chemoembolization (TACE) as a combined therapy for unresectable non-early hepatocellular carcinoma (HCC). *Eur Radiol* 2006; **16**:661–9.
- 25 Dhodapkar MV, Steinman RM, Sapp M *et al.* Rapid generation of broad T-cell immunity in humans after a single injection of mature dendritic cells. *J Clin Invest* 1999; **104**:173–80.
- 26 Orange JS, Brodeur SR, Jain A *et al.* Deficient natural killer cell cytotoxicity in patients with IKK-gamma/NEMO mutations. *J Clin Invest* 2002; **109**:1501–9.
- 27 Klausner RD, Donaldson JG, Lippincott-Schwartz J, Brefeldin A: insights into the control of membrane traffic and organelle structure. *J Cell Biol* 1992; **116**:1071–80.
- 28 Mizukoshi E, Nakamoto Y, Marukawa Y *et al.* Cytotoxic T cell responses to human telomerase reverse transcriptase in patients with hepatocellular carcinoma. *Hepatology* 2006; **43**:1284–94.
- 29 Mizukoshi E, Nakamoto Y, Tsuji H, Yamashita T, Kaneko S. Identification of alpha-fetoprotein-derived peptides recognized by cytotoxic T lymphocytes in HLA-A24+ patients with hepatocellular carcinoma. *Int J Cancer* 2006; **118**:1194–204.
- 30 Mizukoshi E, Honda M, Arai K, Yamashita T, Nakamoto Y, Kaneko S. Expression of multidrug resistance-associated protein 3 and cytotoxic T cell responses in patients with hepatocellular carcinoma. *J Hepatol* 2008; **49**:946–54.
- 31 Rodriguez PC, Quiceno DG, Zabaleta J *et al.* Arginase I production in the tumor microenvironment by mature myeloid cells inhibits T-cell receptor expression and antigen-specific T-cell responses. *Cancer Res* 2004; **64**:5839–49.
- 32 Itoh T, Ueda Y, Okugawa K *et al.* Streptococcal preparation OK432 promotes functional maturation of human monocyte-derived dendritic cells. *Cancer Immunol Immunother* 2003; **52**:207–14.
- 33 Kuroki H, Morisaki T, Matsumoto K *et al.* Streptococcal preparation OK-432: a new maturation factor of monocyte-derived dendritic cells for clinical use. *Cancer Immunol Immunother* 2003; **52**:561–8.
- 34 Gunn MD, Kyuwa S, Tam C *et al.* Mice lacking expression of secondary lymphoid organ chemokine have defects in lymphocyte homing and dendritic cell localization. *J Exp Med* 1999; **189**:451–60.
- 35 Imanishi T, Akaza T, Kimura A, Tokunaga K, Gojobori T. HLA 1991, Proceedings of the Eleventh International Histocompatibility Workshop and Conference. Tokyo: Oxford University Press, 1992.
- 36 Zea AH, Rodriguez PC, Atkins MB *et al.* Arginase-producing myeloid suppressor cells in renal cell carcinoma patients: a mechanism of tumor evasion. *Cancer Res* 2005; **65**:3044–8.
- 37 Chrzanowska A, Krawczyk M, Baranczyk-Kuzma A. Changes in arginase isoenzymes pattern in human hepatocellular carcinoma. *Biochem Biophys Res Commun* 2008; **377**:337–40.
- 38 Caldwell S, Park SH. The epidemiology of hepatocellular cancer: from the perspectives of public health problem to tumor biology. *J Gastroenterol* 2009; **44** (Suppl. 19):96–101.
- 39 Okamoto M, Oshikawa T, Tano T *et al.* Involvement of Toll-like

- receptor 4 signaling in interferon-gamma production and antitumor effect by streptococcal agent OK-432. *J Natl Cancer Inst* 2003; **95**:316–26.
- 40 Liu S, Yu Y, Zhang M, Wang W, Cao X. The involvement of TNF-alpha-related apoptosis-inducing ligand in the enhanced cytotoxicity of IFN-beta-stimulated human dendritic cells to tumor cells. *J Immunol* 2001; **166**:5407–15.
 - 41 Lu G, Janjic BM, Janjic J, Whiteside TL, Storkus WJ, Vujanovic NL. Innate direct anticancer effector function of human immature dendritic cells. II. Role of TNF, lymphotoxin-alpha(1)beta(2), Fas ligand, and TNF-related apoptosis-inducing ligand. *J Immunol* 2002; **168**:1831–9.
 - 42 Nicolas A, Cathelin D, Larmonier N *et al*. Dendritic cells trigger tumor cell death by a nitric oxide-dependent mechanism. *J Immunol* 2007; **179**:812–18.
 - 43 Strydom G, Bangert C, Tauber M, Strohal R, Kopp T, Stingl G. Tumoricidal activity of TLR7/8-activated inflammatory dendritic cells. *J Exp Med* 2007; **204**:1441–51.
 - 44 West E, Morgan R, Scott K *et al*. Clinical grade OK432-activated dendritic cells: *in vitro* characterization and tracking during intralymphatic delivery. *J Immunother* 2009; **32**:66–78.
 - 45 Hirooka Y, Itoh A, Kawashima H *et al*. A combination therapy of gemcitabine with immunotherapy for patients with inoperable locally advanced pancreatic cancer. *Pancreas* 2009; **38**:e69–74.
 - 46 Melief CJ. Cancer immunotherapy by dendritic cells. *Immunity* 2008; **29**:372–83.
 - 47 Zitvogel L, Apetoh L, Ghiringhelli F, Kroemer G. Immunological aspects of cancer chemotherapy. *Nat Rev Immunol* 2008; **8**:59–73.
 - 48 Ayaru L, Pereira SP, Alisa A *et al*. Unmasking of alpha-fetoprotein-specific CD4(+) T cell responses in hepatocellular carcinoma patients undergoing embolization. *J Immunol* 2007; **178**:1914–22.
 - 49 Thurner B, Haendle I, Roder C *et al*. Vaccination with mage-3A1 peptide-pulsed mature, monocyte-derived dendritic cells expands specific cytotoxic T cells and induces regression of some metastases in advanced stage IV melanoma. *J Exp Med* 1999; **190**:1669–78.
 - 50 Banachereau J, Palucka AK, Dhodapkar M *et al*. Immune and clinical responses in patients with metastatic melanoma to CD34(+) progenitor-derived dendritic cell vaccine. *Cancer Res* 2001; **61**:6451–8.
 - 51 Engell-Noerregaard L, Hansen TH, Andersen MH, Thor Straten P, Svane IM. Review of clinical studies on dendritic cell-based vaccination of patients with malignant melanoma: assessment of correlation between clinical response and vaccine parameters. *Cancer Immunol Immunother* 2009; **58**:1–14.
 - 52 Itoh K, Yamada A, Mine T, Noguchi M. Recent advances in cancer vaccines: an overview. *Jpn J Clin Oncol* 2009; **39**:73–80.
 - 53 Sugamura K, Asao H, Kondo M *et al*. The common gamma-chain for multiple cytokine receptors. *Adv Immunol* 1995; **59**:225–77.
 - 54 Temann UA, Geba GP, Rankin JA, Flavell RA. Expression of interleukin 9 in the lungs of transgenic mice causes airway inflammation, mast cell hyperplasia, and bronchial hyperresponsiveness. *J Exp Med* 1998; **188**:1307–20.
 - 55 McMillan SJ, Bishop B, Townsend MJ, McKenzie AN, Lloyd CM. The absence of interleukin 9 does not affect the development of allergen-induced pulmonary inflammation nor airway hyperreactivity. *J Exp Med* 2002; **195**:51–7.
 - 56 de Saint-Vis B, Fugier-Vivier I, Massacrier C *et al*. The cytokine profile expressed by human dendritic cells is dependent on cell subtype and mode of activation. *J Immunol* 1998; **160**:1666–76.
 - 57 Shanmugham LN, Petrarca C, Frydas S *et al*. IL-15 an immunoregulatory and anti-cancer cytokine. Recent advances. *J Exp Clin Cancer Res* 2006; **25**:529–36.
 - 58 Kataoka S, Konishi Y, Nishio Y, Fujikawa-Adachi K, Tominaga A. Antitumor activity of eosinophils activated by IL-5 and eotaxin against hepatocellular carcinoma. *DNA Cell Biol* 2004; **23**:549–60.
 - 59 Simson L, Ellyard JL, Dent LA *et al*. Regulation of carcinogenesis by IL-5 and CCL11: a potential role for eosinophils in tumor immune surveillance. *J Immunol* 2007; **178**:4222–9.
 - 60 Bystry RS, Aluvihare V, Welch KA, Kallikourdis M, Betz AG. B cells and professional APCs recruit regulatory T cells via CCL4. *Nat Immunol* 2001; **2**:1126–32.

Malnutrition Impairs Interferon Signaling Through mTOR and FoxO Pathways in Patients With Chronic Hepatitis C

MASAO HONDA,*[‡] KENJI TAKEHANA,[§] AKITO SAKAI,* YUSUKE TAGATA,[§] TAKAYOSHI SHIRASAKI,[‡] SHINOBU NISHITANI,[§] TAKAHIKO MURAMATSU,^{||} TATSUYA YAMASHITA,* YASUNARI NAKAMOTO,* EISHIRO MIZUKOSHI,* YOSHIO SAKAI,* TARO YAMASHITA,* MIKIKO NAKAMURA,* TETSURO SHIMAKAMI,^{||} MINKYUNG YI,[#] STANLEY M. LEMON,^{||} TETSUO SUZUKI,** TAKAJI WAKITA,** SHUICHI KANEKO,* and the Hokuriku Liver Study Group

*Department of Gastroenterology, [‡]Department of Advanced Medical Technology, Kanazawa University Graduate School of Medicine, Kanazawa, Japan; [§]Exploratory Research Laboratories, Research Center, Ajinomoto Pharmaceuticals, Co, Ltd, Kanagawa, Japan; ^{||}Frontier Research Labs, Institute for Innovation, Ajinomoto, Co, Inc, Kanagawa, Japan; ^{||}Division of Infectious Diseases, School of Medicine, The University of North Carolina at Chapel Hill, Chapel Hill, North Carolina; [#]Center for Hepatitis Research, Institute for Human Infections and Immunity, and Department of Microbiology and Immunology, University of Texas Medical Branch, Galveston, Texas; and ^{**}Department of Virology II, National Institute of Infectious Diseases, Tokyo, Japan

BACKGROUND & AIMS: Patients with advanced chronic hepatitis C (CH-C) often are malnourished, but the effects of malnutrition on interferon (IFN) signaling and response to treatment have not been determined. We assessed the importance of the nutritional state of the liver on IFN signaling and treatment response. **METHODS:** We studied data from 168 patients with CH-C who were treated with the combination of pegylated-IFN and ribavirin. Plasma concentrations of amino acids were measured by mass spectrometry. Liver gene expression profiles were obtained from 91 patients. Huh-7 cells were used to evaluate the IFN signaling pathway, mammalian target of rapamycin complex 1 (mTORC1), and forkhead box O (FoxO). Antiviral signaling induced by branched-chain amino acids (BCAAs) was determined using the in vitro hepatitis C virus replication system. **RESULTS:** Multivariate logistic regression analysis showed that Fischer's ratio was associated significantly with nonresponders, independent of interleukin-28B polymorphisms or the histologic stage of the liver. Fischer's ratio was correlated inversely with the expression of BCAA transaminase 1, and was affected by hepatic mTORC1 signaling. IFN stimulation was impaired substantially in Huh-7 cells grown in medium that was low in amino acid concentration, through repressed mTORC1 signaling, and increased Socs3 expression, which was regulated by Foxo3a. BCAA could restore impaired IFN signaling and inhibit hepatitis C virus replication under conditions of malnutrition. **CONCLUSIONS: Malnutrition impaired IFN signaling by inhibiting mTORC1 and activating Socs3 signaling through Foxo3a. Increasing BCAAs to up-regulate IFN signaling might be used as a new therapeutic approach for patients with advanced CH-C.**

Keywords: HCV; Liver Disease; Therapy; Diet.

Interferon (IFN) and ribavirin (RBV) combination therapy is a popular modality for treating patients with chronic hepatitis C (CH-C), but approximately 50% of patients usually relapse, particularly those with hepatitis C virus (HCV) genotype 1b and a high viral load.¹

Recent landmark studies of genome-wide associations identified genomic loci associated with treatment responses to pegylated (Peg)-IFN and RBV combination therapy,^{2,3} and a polymorphism in the interleukin (IL)-28B gene was found to predict hepatitis C treatment-induced viral clearance. Moreover, we previously showed that expression of hepatic IFN-stimulated genes (ISGs) was associated with the IL-28B polymorphism and might contribute to the treatment response.⁴ In addition to the IL-28B polymorphism, host factors such as fibrosis stage and metabolic status of the liver might be associated with the treatment outcome^{4,5}; however, the significance of these factors in conjunction with the IL-28B polymorphism has not been evaluated fully.

In CH-C livers, prolonged liver cell damage, fibrosis development, and microcirculation failure can lead to a state of malnutrition in hepatocytes, resulting in the impairment of multiple metabolic pathways. In patients with advanced stage CH-C, hypoalbuminemia and decreased plasma values for the Fischer's ratio of branched-amino acids (BCAA; leucine, isoleucine, and valine) to aromatic amino acids (tyrosine and phenylalanine) commonly are observed. BCAA are the essential amino acids necessary for ammonium metabolism in muscle when the liver is unable to perform this function. Recent reports have shown that BCAA activates albumin synthesis in rat

Abbreviations used in this paper: BCAA, branched-chain amino acid; BCAT1, branched chain amino-acid transaminase 1; CH-C, chronic hepatitis C; CHIP, chromatin immunoprecipitation; DMEM, Dulbecco's modified Eagle medium; FBE, Foxo binding element; FBEmut, Foxo binding element mutant; FoxO, forkhead box, subgroup O; GLuc, Gaussia luciferase; IFN, interferon; IL, interleukin; ISG, interferon-stimulated genes; mTOR, mammalian target of rapamycin; mTORC1, mammalian target of rapamycin complex 1; NR, no response; PCR, polymerase chain reaction; Peg, pegylated; p-mTOR, phosphorylated form of mammalian target of rapamycin; pS6K, phosphorylated form of p70 S6 protein kinase; pSTAT1, phosphorylated form of signal transducer and activator of transcription 1; Raptor, regulatory associated protein of mTOR; RBV, ribavirin; S6K, p70 S6 protein kinase; siRNA, small interfering RNA; SVR, sustained viral response; TR, transient response.

© 2011 by the AGA Institute

0016-5085/\$36.00

doi:10.1053/j.gastro.2011.03.051

primary hepatocytes⁶ and cirrhotic rat liver⁷ through mammalian target of rapamycin (mTOR) signaling, a central regulator of protein synthesis, by sensing nutrient conditions.⁸ Thus, peripheral amino acid composition is closely related to signaling pathways in the liver.

In addition to metabolic aspects, recent reports have elucidated new functional roles for mTOR in the IFN signaling pathway. Targeted disruptions of tuberous sclerosis 2 and eukaryotic translation initiation factor 4E binding protein 1, which both inhibit mTOR complex 1 (mTORC1) signaling, substantially enhanced IFN- α -dependent antiviral responses.^{9,10} Therefore, mTORC1 signaling might be involved in the antiviral response as well as in metabolic processes. However, these issues have not yet been addressed in terms of IFN treatment for CH-C. In the present study, therefore, we evaluated the clinical relevance of the nutritional state of the liver, as estimated by the plasma Fischer's ratio, on Peg-IFN and RBV combination therapy. We also evaluated antiviral signaling induced by BCAA using an in vitro HCV replication system.

Materials and Methods

Patients

A total of 168 patients with CH-C at the Graduate School of Medicine at Kanazawa University Hospital (Kanazawa, Japan) and its related hospitals in Japan (Table 1, Supplementary Table 1) were evaluated in the present study. The clinical characteristics of these patients have been described previously.⁴ All patients were administered Peg-IFN- α 2b (Schering-Plough K.K., Tokyo, Japan) and RBV combination therapy for 48 weeks. The definition of the treatment response was as follows: sustained viral response (SVR), clearance of HCV viremia 24 weeks after the cessation of therapy; transient response (TR), no detectable HCV viremia at the cessation of therapy but relapse during the follow-up period; and no response (NR). Genetic variation of the IL-28B polymorphism at rs8099917 was evaluated in all patients using TaqMan Pre-Designed SNP Genotyping Assays (Applied Biosystems, Carlsbad, CA) as described previously.⁴ Gene expression profiling in the liver was performed in 91 patients using the Affymetrix Human 133 Plus 2.0 microarray chip (Affymetrix, Santa Clara, CA) as described previously (Supplementary Table 1).⁴

Plasma Amino Acid Analysis

Amino acid concentrations in plasma samples were measured by high-performance liquid chromatography-electrospray ionization-mass spectrometry, followed by derivatization.¹¹ Detailed experimental procedures are described in the Supplementary Materials and Methods section.

Culture Medium

Huh-7 and Huh-7.5 cells (kindly provided by Professor C. M. Rice, Rockefeller University, New York, NY) were maintained in Dulbecco's modified Eagle medium (DMEM; Gibco BRL, Gaithersburg, MD) containing 10%

fetal bovine serum and 1% penicillin/streptomycin (normal medium). Amino acid-free medium (ZERO medium) was prepared by mixing 5.81 g nutrition-free DMEM (Nacalai Tesque, Kyoto, Japan), 1.85 g NaHCO₃, 1 g glucose, and 0.5 mL 1M (mol/L) sodium pyruvate in 500 mL Milli-Q water, then sterilizing with a 0.22- μ m filter (Millipore, Billerica, MA). Low amino acid media ($\times 1/5$, $\times 1/10$, $\times 1/30$, and $\times 1/100$ DMEM) were prepared by diluting $\times 1$ DMEM with ZERO medium. Powdered BCAA (leucine-isoleucine-valine, 2:1:1.2) (Ajinomoto Pharma, Tokyo, Japan) was freshly dissolved with distilled water at 100 mmol/L, then applied to cultured medium at 2 mmol/L, 4 mmol/L, or 8 mmol/L.

Western Blotting and Immunofluorescence Staining

A total of 1.5×10^5 Huh-7 cells were seeded in normal medium 24 hours before performing the experiments. The medium was changed to low-amino-acid medium and maintained for up to 24 hours. Western blotting was performed as previously described.¹² Cells were washed in phosphate-buffered saline (PBS) and lysed in RIPA buffer containing complete Protease Inhibitor Cocktail and PhosSTOP (Roche Applied Science, Indianapolis, IN). The membranes were blocked in Blocking One-P (Nacalai Tesque). The antibodies used for Western blotting are summarized in the Supplementary Materials and Methods section.

For immunofluorescence staining, cells were fixed with 4% paraformaldehyde in PBS, then permeabilized with 0.1% Triton-X 100 in PBS. The primary anti-forkhead box O (Foxo)3a antibody (Abcam, Cambridge, MA) was used at a final concentration of 2 μ g/mL in PBS containing 2% fetal bovine serum at 4°C for 16 hours. Incubation with the Alexa Fluor 488-conjugated secondary antibody (Invitrogen, Carlsbad, CA) at a 500-fold dilution in PBS containing 3% fetal bovine serum antibody was performed for 4 hours, and cells were stained with Hoechst 33258 to visualize nuclear DNA (Vector Laboratories, Burlingame, CA).

Quantitative Real-Time Detection Polymerase Chain Reaction

A total of 1.5×10^5 Huh-7 cells were seeded in normal medium 24 hours before performing the experiments. The medium was changed to low-amino-acid medium, to which IFN- α and/or BCAA was added, and maintained for 24 hours. Rapamycin treatment (100 nmol/L) was performed for 30 minutes in normal medium before a medium change. RNA was isolated using TriPure isolation reagent (Roche Applied Science), and complementary DNA (cDNA) was synthesized using the High Capacity cDNA reverse transcription kit (Applied Biosystems, Carlsbad, CA). Real-time detection polymerase chain reaction (PCR) was performed using the 7500 Real-Time PCR System (Applied Biosystems) and Power SYBR Green PCR Master Mix (Applied Biosystems) containing specific primers according to the manufacturer's

Table 1. Comparison of Clinical Factors Between Patients With and Without NR

Clinical category	SVR+TR	NR	Univariate P value	Multivariate odds (95% CI)	Multivariate P value
Patients, n	125	43		—	
Age and sex					
Age, y	57 (30–72)	56 (30–73)	.927	—	
Sex, male vs female	68 vs 57	24 vs 19	.872	—	
Liver histology					
F stage (F1–2 vs F3–4)	95 vs 30	20 vs 23	.001	6.35 (2.02–23.7)	.001
A grade (A0–1 vs A2–3)	68 vs 57	19 vs 24	.248	—	
Host gene factors					
IL-28B (TT vs TG/GG) ^a	109 vs 12	12 vs 31	<.001	19.7 (5.74–82.7)	<.001
ISGs (Mx, IFI44, IFIT1), (<3.5 vs ≥3.5)	103 vs 22	12 vs 31	<.001	5.26 (1.65–17.6)	.005
Metabolic factors					
BMI, kg/m ²	23.2 (16.3–34.7)	23.4 (19.5–40.6)	.439	—	
TG, mg/dL	98 (30–323)	116 (45–276)	.058	—	
T-Chol, mg/dL	167 (90–237)	160 (81–214)	.680	—	
LDL-Chol, mg/dL	82 (36–134)	73 (29–123)	.019	—	
HDL-Chol, mg/dL	42 (20–71)	47 (18–82)	.098	—	
FBS, mg/dL	94 (60–291)	96 (67–196)	.139	—	
Insulin, μU/mL	6.6 (0.7–23.7)	6.8 (2–23.7)	.039	—	
HOMA-IR	1.2 (0.3–11.7)	1.2 (0.4–7.2)	.697	—	
Fischer ratio	2.3 (1.5–3.3)	2.1 (1.5–2.8)	.005	8.91 (1.62–55.6)	.011
Other laboratory parameters					
AST level, IU/L	46 (18–258)	64 (21–283)	.017	—	
ALT level, IU/L	60 (16–376)	82 (18–345)	.052	—	
γ-GTP level, IU/L	36 (4–367)	75 (26–392)	<.001	—	
WBC, /mm ³	4800 (2100–11100)	4800 (2500–8200)	.551	—	
Hb level, g/dL	14 (9.3–16.6)	14.4 (11.2–17.2)	.099	—	
PLT, ×10 ⁴ /mm ³	15.7 (7–39.4)	15.2 (7.6–27.8)	.378	—	
Viral factors					
ISDR mutations ≤1 vs ≥2	80 vs 44	34 vs 9	.070	4.12 (1.25–15.9)	.019
HCV-RNA, KIU/mL	2300 (126–5000)	1930 (140–5000)	.725	—	
Treatment factors					
Total dose administered					
Peg-IFN, μg	3840 (960–7200)	3840 (1920–2880)	.916	—	
RBV, g	202 (134–336)	202 (36–336)	.531	—	
Achieved administration rate					
Peg-IFN, %					
≥80%	84	28	.975	—	
<80%	42	14			
RBV (%)					
≥80%	76	24	.745	—	
<80%	50	18			
Achievement of EVR	101/125 (81%)	0/43 (0%)	<.001	—	

BMI, body mass index; CI, confidence interval; FBS, fasting blood sugar; γ-GTP, gamma-glutamyl transpeptidase; Hb, hemoglobin; HDL-chol, high density lipoprotein cholesterol; LDL-chol, low density lipoprotein cholesterol; PLT, platelets; T-chol, total cholesterol; TG, triglycerides; WBC, leukocytes.

^aIL-28B SNP at rs8099917.

instructions. The primer sequence for real-time detection PCR is given in the Supplementary Materials and Methods section. HCV RNA was detected as described previously¹² and expression was standardized to that of glyceraldehyde-3-phosphate dehydrogenase.

Reporter Assay

Construction of the interferon stimulated response element (ISRE)-luc reporter plasmid and Socs3-luc or Socs3 (FoxO binding element mutant [FBEmut])-luc reporter plasmids is described in the Supplementary Materials and Methods section.

Huh-7 cells were transfected with the ISRE-luc reporter plasmid 24 hours before IFN-alfa treatment. Cells were

treated with IFN-alfa (0 or 100 U/mL) and BCAA (2 mmol/L) in low-amino-acid media. After 24 hours, luciferase activities were measured using the Dual Luciferase assay system (Promega, Madison, WI). For Socs3 promoter activities, Huh-7 cells were transfected with Socs3-luc or Socs3 (FBEmut)-luc reporter plasmids together with the Foxo3a expression plasmid, and luciferase activities were measured after 24 hours. Values were normalized to the luciferase activity of the co-transfected pGL4.75 Renilla luciferase-expressing plasmid (Promega).

Knockdown Experiments

Huh-7 cells were transfected with Ctrl (Stealth RNAi Negative Control Low GC Duplex #2; Invitrogen) or

targets (regulatory associated protein of mTOR [Raptor] and Foxo3a) (Supplementary Materials and Methods) small interfering RNA (siRNA) using Lipofectamine RNAiMAX reagent (Invitrogen) according to the manufacturer's instructions. After 48 hours, cells were cultured in normal or low-amino-acid media for a further 24 hours. The knockdown effect was confirmed by Western blotting.

Chromatin Immunoprecipitation Assay

Detailed experimental procedures are described in the Supplementary Materials and Methods section.

HCV Replication Analysis

pH77S3 is an improved version of pH77S, a plasmid containing the full-length sequence of the genotype 1a H77 strain of HCV with 5 cell culture-adaptive mutations that promote its replication in Huh-7 hepatoma cells.¹³ pH77S.3/Gaussia luciferase (GLuc)2A is a related construct in which the GLuc sequence, fused to the 2A autocatalytic protease of foot-and-mouth virus RNA, was inserted in-frame between p7 and NS2¹⁴ (Supplementary Materials and Methods). A signal sequence in GLuc directs its secretion into cell culture media, allowing real-time, dynamic measurements of GLuc expression to be performed without the need for cell lysis.

A 10- μ g aliquot of synthetic RNA transcribed from pH77S.3/GLuc2A was used for electroporation. Cells were pulsed at 260 V and 950 μ F using the Gene Pulser II apparatus (Bio-Rad Laboratories, Hercules, CA) and plated in fresh normal medium for 12 hours to recover. Cell medium was changed to \times 1 DMEM without serum for 8 hours, then changed to low-amino-acid medium containing 0–8 mmol/L BCAA for a further 24 hours. Cells and culture medium were collected and used for GLuc assays, real-time detection PCR, and Western blotting. The number of viable cells was determined by a (3-[4,5-dimethylthiazol-2-yl]-5-[3-carboxymethoxyphenyl]-2-[4-sulfophenyl]-2H-tetrazolium, inner salt) assay (Promega).

Continuously JFH-1-infecting Huh-7 cells were obtained by the infection of Huh-7 cells with JFH-1 cell culture-derived HCV at a multiplicity of infection of 0.01. Cells were maintained in normal medium by passaging every 3–4 days for approximately 6 months. About 20%–30% of the cells consistently were positive for HCV core protein (Supplementary Figure 4). Culture medium of JFH-1-infecting Huh-7 cells was changed to the low-amino-acid medium containing 0–8 mmol/L BCAA for 24 hours. Cells then were collected and used for assays.

Statistical Analysis

Results are expressed as mean \pm standard deviation. Significance was tested by 1-way analysis of variance with the Bonferroni method, and differences were considered statistically significant at a *P* value of less than .05.

Results

Fischer's Ratio as a Predictive Factor for Treatment Response

The clinical characteristics of patients who received Peg-IFN and RBV combination therapy are shown in Table 1 and Supplementary Table 1, and explanations of these characteristics have been described previously.⁴ All patients were infected with HCV genotype 1b and had a high viral load (>100 IU/mL). We compared patients with SVR + TR against those with NR, as assessed by the overall plausibility of treatment response groups using Fisher's C statistic as previously described.⁴ We included data on the IL-28B polymorphism and plasma amino acid composition (aminogram).

Univariate regression analysis showed that no single amino acid was associated significantly with treatment response; however, using Fischer's ratio, the BCAA (Ile+Leu+Val)/aromatic amino acids (Phe+Tyr) ratio was associated significantly with treatment response (*P* = .005) (Table 1). Of the 121 patients with IL-28B major type, SVR, TR, and NR were observed in 53%, 37%, and 10%, respectively, and among 33 patients with IL-28B minor type, SVR, TR, and NR were observed in 15%, 17%, and 68%, respectively (*P* < .001) (data not shown). Fischer's ratio of SVR, TR, and NR was 2.35 ± 0.38 , 2.30 ± 0.29 , and 2.10 ± 0.31 , respectively (*P* < .015) (data not shown).

We selected IL-28B polymorphism, hepatic ISG expression, fibrosis stage, HCV RNA, interferon sensitivity determining region mutation, and Fischer's ratio as factors for multivariate analysis. Multivariate analysis revealed that the minor type of IL-28B polymorphism (TG or GG at rs8099917) (odds ratio, 19.7; *P* < .001), advanced fibrosis stage of the liver (F3–4) (odds ratio, 6.35; *P* = .001), high hepatic ISGs (≥ 3.5) (odds ratio, 5.26; *P* = .005), low Fischer's ratio (continuous range, 1.5–3.3) (unit odds, 8.91; *P* = .011), and presence of ISDR mutation (≤ 1) (odds ratio, 4.12; *P* = .019) independently contributed to NR (Table 1).

The distribution of the Fischer's ratio according to fibrosis stage is shown in Supplementary Figure 1. The ratio decreased significantly in advanced fibrosis stage (F3–4) compared with early fibrosis stage (F1). No significant association between major or minor type of IL-28B polymorphism and different fibrosis stages of the liver was observed (Supplementary Figure 1A). In early fibrosis (F1–2) (Supplementary Figure 1B), 90% (80 of 89) of SVR+TR cases had the major type of IL-28B polymorphism, and 94% (16 of 17) of NR cases had the minor type. However, in the advanced fibrosis stage of the liver (F3–4) (Supplementary Figure 1C), 85% (23 of 27) of SVR+TR cases had the major type of IL-28B polymorphism and 50% (10 of 20) of NR cases had the minor type. Thus, in advanced fibrosis stages, factors other than the IL-28B polymorphism appear to contribute to NR. Interestingly, the Fischer's ratio was significantly lower in NR patients than SVR+TR pa-

tients in the advanced fibrosis stage of the liver. Therefore, Fischer's ratio could be an important predictor for NR that is independent of IL-28B polymorphism and histologic stage of the liver.

Fischer's Ratio and mTORC1 Signaling in CH-C Livers

Hepatic gene expression in 91 of 168 patients (Supplementary Table 1) was obtained using Affymetrix genechip analysis as described previously.⁴ To examine the relationship between the plasma Fischer's ratio and mTORC1 signaling in the liver we evaluated the expression of key regulatory genes related to mTORC1 signaling. We found that expression of branched chain amino acid transaminase 1 (BCAT1), an important catalytic enzyme of BCAA, was significantly negatively correlated with Fischer's ratio (Figure 1A). This indicates that the plasma Fischer's ratio is regulated in the liver as well as in peripheral muscle. Interestingly, the expression of *c-myc*, a positive regulator of BCAT1 (Figure 1C),¹⁵ was correlated negatively with the Fischer's ratio (Figure 1B). The expression of PDCD4, a negative transcriptional target of ribosomal p70 S6 protein kinase (S6K), downstream of mTORC1, was correlated significantly with BCAT1 (Figure 1D and E). Thus, in CH-C livers, BCAT1 is induced with progressive liver disease and mTORC1 signaling is repressed, a process that might involve *c-myc*. Fischer's ratio of the plasma therefore can be seen to reflect mTORC1 signaling in the liver.

Impaired IFN Signaling in Huh-7 Cells Grown in Low-Amino-Acid Medium

Recent reports have shown the functional relevance of mTOR on IFN signaling and antiviral responses.^{9,10} To evaluate IFN- α signaling and the mTOR pathway, we used Huh-7 cells grown in different amino acid conditions ($\times 1$ DMEM, $\times 1/5$ DMEM, $\times 1/30$ DMEM, and $\times 1/100$ DMEM). The phosphorylated forms of mTOR (p-mTOR) and S6K (pS6K), an important downstream regulator of mTORC1 signaling, were decreased substantially in $\times 1/30$ DMEM and $\times 1/100$ DMEM (Figure 2A). Interestingly, the expression of the phosphorylated form of signal transducer and activator of transcription 1 (pSTAT1), an essential transducer of type 1 IFN signaling, also was decreased in these conditions (Figure 2A). Similarly, the expression of p-mTOR and pSTAT1 was repressed significantly in CH-C livers with a low Fischer's ratio compared with those with a high Fischer's ratio (Supplementary Figure 2, Supplementary Table 2).

To examine whether decreased pSTAT1 expression might be owing to repressed mTORC1 signaling, we knocked down the expression of Raptor, a specific subunit of mTORC1. We achieved more than 50% knockdown of Raptor by specific siRNA (Figure 2B). Under these conditions, the expression of p-mTOR and pS6K were repressed, which is consistent with previous reports.¹⁶ The expression of pSTAT1 also was repressed after Raptor knockdown (Figure 2B).

CLINICAL LIVER




Figure 1. Regression analysis of mTORC1-related gene expression in liver. Gene expression values were determined by probe intensities. (A) BCAT1 and Fischer's ratio. (B) *c-myc* and Fischer's ratio. (C) BCAT1 and *c-myc*. (D) PDCD4 and BCAT1. (E) Putative signaling of mTORC1-related genes in CH-C.




Figure 2. mTORC1 and IFN signaling in Huh-7 cells in low-amino-acid media. (A) p-mTOR, pS6K, and pSTAT1 expression in different amino acid media. (B) p-mTOR, pS6K, and pSTAT1 expression under Raptor knock-down conditions. (C) IFN- α stimulation and pSTAT1 expression in low-amino-acid media or under Raptor knock-down conditions. (D) IFN- α stimulation and ISRE reporter activities in normal and low-amino-acid media. (E) IFN- α stimulation and 2'5'OAS expression supplemented with BCAA or rapamycin in low-amino-acid medium. (F) Chromatin immunoprecipitation of 2'5'OAS promoter region by ISGF3 γ .

The induction of pSTAT1 by IFN- α (1000 U/mL) stimulation was impaired in $\times 1/5$ DMEM or in Raptor knocked-down condition, compared with the control (Figure 2C). Consistent with these results, IFN- α -induced ISRE-dependent transcriptional activity, as measured using an ISRE-luciferase reporter assay, was impaired significantly in $\times 1/5$ DMEM compared with $\times 1$ DMEM (Figure 2D). However, this activity could be rescued by the addition of 2 mmol/L BCAA (Figure 2D). These results were confirmed by determining the expression of the endogenous IFN- α responsive gene, 2'5'OAS, using quantitative reverse-transcription PCR. Figure 2E shows that BCAA treatment augmented 2'5'OAS expression in low levels of amino acids, and that this could be reversed by the addition of rapamycin, an inhibitor of mTORC1 (Figure 2E). Furthermore, chromatin immunoprecipitation (ChIP) experiments revealed that transcriptional augmentation by BCAA was mediated by the binding of the IFN- α -inducible transcription factor, ISGF3 γ , to the promoter region of 2'5'OAS (Figure 2F). These results indicate that

amino acids in culture media play an essential role in IFN- α signaling through mTORC1 signaling, and that the addition of BCAA can overcome impaired IFN- α signaling in Huh-7 cells.

Induction of Socs3 in Low-Amino-Acid Medium in Huh-7 Cells

Besides being involved in mTOR signaling, Foxo transcriptional factors mediate another important branch of nutrition-sensing signaling pathway.¹⁷ Therefore, we evaluated forkhead box O3A (Foxo3a) expression in low-amino-acid conditions in Huh-7 cells. After 6 hours culture in $\times 1/5$, $\times 1/30$, and $\times 1/100$ DMEM, expression of the phosphorylated form of Foxo3a (pFoxo3a) decreased, whereas that of total Foxo3a increased in $\times 1/5$ and $\times 1/30$ DMEM, and the ratio of pFoxo3a to Foxo3a (pFoxo3a/Foxo3a) substantially decreased (Figure 3A and B). It has been reported that dephosphorylated Foxo3a is translocated to the nucleus before activation of its target genes.¹⁸ In the present study, immunofluorescent staining




Figure 3. Foxo3a and Socs3 signaling in Huh-7 cells in low-amino-acid medium. (A) Foxo3a and Socs3 expression in different amino acid media. (B) Relative change of pFoxo3a/Foxo3a and Socs3 expression in different amino acid media. (C) Immunofluorescence staining of Foxo3a in Huh-7 cells in normal and low-amino-acid media. (D) Relative change of Socs3 messenger RNA in Huh-7 cells in normal and low-amino-acid media. (E) Regression analysis of Socs3 in liver and Fischer's ratio. (F) Regression analysis of Socs3 and Foxo3a in liver.

with an anti-Foxo3a antibody showed that Foxo3a diffused in both the cytoplasm and nucleus in normal amino acid medium, but localized in the nucleus in low-amino-acid medium ($\times 1/10$ DMEM) (Figure 3C).

Interestingly, in low-amino-acid medium, transcription and protein expression of Socs3 increased significantly (Figure 3A, B, and D). The induction of Socs3 in a state of malnutrition also was confirmed in clinical samples. In CH-C livers there was a significant negative correlation

between the plasma Fischer's ratio and Socs3 expression, implying that Socs3 expression increases during the malnutrition state induced by CH-C. There was also a significant correlation between Foxo3a and the transcriptional level of Socs3 in CH-C livers (Figure 3E and F), suggesting an *in vitro* and *in vivo* biological role for Foxo3a in the activation of Socs3 expression. These findings also were confirmed by Western blotting of CH-C livers (Supplementary Figure 2, Supplementary Table 2).

Socs3 Is a Transcriptional Target of Foxo3a

The significant correlation between *Socs3* and *Foxo3a* in CH-C livers prompted us to analyze the *Socs3* promoter sequence and, in doing so, we identified a putative *Foxo* binding element (FBE) (Figure 4A). To investigate the functional relevance of *Foxo3a* in the transcriptional regulation of *Socs3*, we constructed reporter plasmids containing a luciferase coding region fused to the *Socs3* promoter region (*Socs3-luc*). *Socs3-luc* promoter activity was increased substantially by the overexpression of *Foxo3a* (Figure 4B). The mutations introduced in the putative FBE (FBEmut) in the *Socs3* promoter significantly reduced *Foxo3a*-induced *Socs3* promoter activation (Figure 4B).

Foxo3a then was knocked down by siRNA and *Socs3* induction was evaluated. After suppression of *Foxo3a* (Supplementary Figure 3), *Socs3* promoter activity was repressed significantly in low-amino-acid medium ($\times 1/10$ DMEM) (Figure 4C). Thus, *Foxo3a* appears to be indispensable for activating the *Socs3* promoter under low-amino-acid conditions. Correlating with these results, ChIP assays using an anti-*Foxo3a* antibody showed a significant increase in the association between *Foxo3a* and the FBE of the *Socs3* promoter in low-amino-acid conditions ($\times 1/10$ DMEM) (Figure 4D). Taken together, these results suggest that, besides mTORC1 signaling, the *Foxo3a*-mediated *Socs3* signaling pathway might contribute to impaired IFN signaling in a state of malnutrition in CH-C. BCAA potentially restores this signaling (Figure 4E).

Effect of BCAA on HCV Replication in Huh-7 or Huh-7.5 Cells

Based on the earlier-described results, we used 2 HCV in vitro replication systems to examine whether BCAA affects HCV replication in Huh-7 or Huh-7.5 cells. The first system used a recombinant infectious genotype 1a clone, H77S.3/GLuc2A (Supplementary Materials and Methods, Supplementary Figure 4), including reporter genes, whereas the second used continuously JFH-1-infecting Huh-7 cells (Supplementary Materials and Methods).

The synthetic RNA transcribed from pH77S.3/GLuc2A was introduced into Huh-7.5 cells and replication of H77S.3/GLuc2A was evaluated in normal or low-amino-acid medium supplemented with BCAA. H77S.3/GLuc2A increased significantly by 2.6-fold in Huh-7.5 cells grown in low-amino-acid medium ($\times 1/5$ DMEM) compared with normal amino acid medium ($\times 1$ DMEM). Interestingly, BCAA repressed H77S.3/GLuc2A replication in a dose-dependent manner (Figure 5A). In agreement with these results, the expression of *Mx-1* was increased significantly by the addition of BCAA (Figure 5B). Similar findings were observed in JFH-1-infecting Huh-7 cells (Materials and Methods, Supplementary Figure 4). Although no obvious increase in HCV replication was observed in low-amino-acid medium ($\times 1/5$ DMEM) com-

pared with normal amino acid medium ($\times 1$ DMEM), JFH-1 replication was repressed significantly by the addition of BCAA in a dose-dependent manner (Figure 5D). The expression of *Mx-1* was increased substantially by the addition of BCAA (Figure 5E), suggesting that BCAA significantly repressed HCV replication in cells with either naive or persistent HCV infection. Importantly, there were no significant differences in cell viability between the conditions (Figure 5C and F).

To validate these findings, signaling pathways in HCV replicating cells were examined (Figure 6A and B). BCAA increased pS6K in a dose-dependent manner, implying its involvement in the activation of mTORC1 signaling. Related to this, expression of pSTAT1 was shown to be increased and the ratio of pSTAT1 to total STAT1 (pSTAT1/STAT1) increased 2.5- to 3-fold after the addition of BCAA. Thus, BCAA activated mTORC1 and the JAK-STAT signaling pathway in HCV-infected cells. In addition, the expression ratio of p*Foxo3a* to total *Foxo3a* (p*Foxo3a*/*Foxo3a*) increased 3- to 4-fold, indicating an increase in the cytoplasmic form of *Foxo3a* that is exposed to proteasome degradation. Concordant with these findings, we observed a decrease in the expression of *Socs3*. In addition, expression of the HCV core protein decreased as shown in Figure 6A and B. Thus, these results clearly show that BCAA repressed HCV replication through activation of IFN signaling and repression of *Socs3*-mediated IFN inhibitory signaling, as proposed in Figure 4E.

Discussion

Thompson et al⁵ showed that the IL-28B polymorphism, HCV RNA, nationality (Caucasian/Hispanic vs African American), hepatic fibrosis stage, and fasting blood sugar level are all significant variables for achieving SVR in patients infected with genotype 1 HCV. However, the significance of variable factors for treatment response in conjunction with the IL-28B polymorphism has not been evaluated fully. In the present study, in addition to previously examined variables,⁴ we included the plasma Fischer's ratio as a nutritional parameter. Multivariate analysis showed that the minor type of IL-28B polymorphism, advanced fibrosis stage, high hepatic ISGs, low Fischer's ratio, and ISDR mutation (≤ 1) independently contributed to NR (Table 1). Interestingly, among patients of similar fibrosis stage (F3-4), the Fischer's ratio was significantly lower in NR than SVR+TR cases. Therefore, the plasma value of Fischer's ratio was associated with the treatment response that was independent of the IL-28B polymorphism and histologic stage of the liver, although patients with advanced hepatic fibrosis are likely to be nutritionally affected.

As a nutrient sensor signaling pathway, the protein kinase mTOR plays an essential role in maintaining homeostasis and regulates protein synthesis in response to nutrient conditions. mTOR is the catalytic subunit of 2 distinct complexes, mTORC1 and mTORC2. In addition




Figure 5. Effect of BCAA on HCV replication in cells in low-amino-acid medium. (A) Effect of BCAA on H77S.3/Gluc2A replication in Huh-7.5 cells. (B) Mx-1 expression in H77S.3/Gluc2A-transfected Huh-7.5 cells supplemented with BCAA. (C) Viability of Huh-7.5 cells. (D) Effect of BCAA on JFH-1 replication continuously infecting Huh-7 cells. (E) Mx-1 expression in continuously JFH-1-infected Huh-7 cells supplemented with BCAA. (F) Viability of Huh-7 cells.

to these metabolic aspects, recent reports have shown that mTORC1 participates in IFN signaling and antiviral defense responses,^{9,10} although the precise signaling pathway has not yet been clarified. In the present study, we evaluated mTORC1 signaling in CH-C livers using gene expression profiling of 91 patients (Figure 1, Supplementary Table 1). We observed a significant negative correlation between plasma Fischer's ratio and hepatic expression of BCAT1, an important catalytic enzyme of BCAA (Figure 1A). Moreover, BCAT1 expression was correlated positively with PDCD4 expression, which in turn is regulated negatively by pS6K at the transcriptional level (Figure 1D).¹⁶ Thus, the expression of BCAT1 appears to be a negative indicator of mTORC1 signaling in the liver, and the plasma Fischer's ratio is partially reflected by mTORC1 signaling in the liver and muscle.

Interestingly, the expression of c-myc was correlated significantly with BCAT1 (Figure 1C) as reported previously.¹⁵ Several studies observed up-regulated c-myc expression in advanced stages of CH-C¹⁹ but, on the other hand, c-myc recently was shown to be a target of

mTORC1 in hepatic cells.¹⁷ The existence of a feedback mechanism between c-myc and mTORC1 signaling to maintain liver homeostasis (Figure 1E) is plausible, although the precise mechanisms need to be confirmed.

Impaired mTORC1 signaling is suggested to affect the IFN- α -induced signaling pathway. To address this, the relationship between mTORC1 and IFN signaling was assessed using a cell culture system. In low-amino-acid medium ($\times 1/5$, $\times 1/30$, and $\times 1/100$ DMEM), expression of pSTAT1 was decreased substantially, correlating with the impaired mTORC1 signaling represented by decreased p-mTOR and pS6K expression in Huh-7 cells (Figure 2A).

The relationship between mTORC1 and IFN signaling was confirmed further by the knock-down experiment of Raptor, a specific subunit of mTORC1 (Figure 2B), although a more precise analysis should be performed to confirm this relationship. Importantly, when Huh-7 cells were stimulated by IFN- α , pSTAT1 induction was repressed significantly in low-amino-acid medium ($\times 1/5$ DMEM) or in Raptor knocked-down conditions (Figure 2C). It therefore could be speculated that IFN treat-